Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Sep 2, 2026 · Filed Sep 4, 2026
A board member of ResMed| sold $228K of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$227,688
Shares × reported transaction price
27 days after results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $230.87 on Sep 2, 2026, 26% above its 52-week low and 19% below its high, after a 20% rise over the previous 30 trading days
52-week range $182.82 (Jun 2, 2026) to $283.28 (Oct 7, 2025), 48% of the way up, from 252 adjusted closes. 30 trading days earlier: $192.91 on Jul 22, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.8% | -1.1% | +4.9% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
